SPECIFIC PROPERTIES OF THE DRUG AMANTADINE AGAINST VIRUSES AND IN PARKINSON'S DISEASE

Long-term therapy of Parkinson's disease (PD) with dopaminergic agents is naturally accompanied by the appearance of symptom fluctuations and dyskinesias, and these complications are an extremely important factor that adversely affects the quality of life.

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-01-26
DOI
https://doi.org/10.5281/zenodo.14743087
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

SPECIFIC PROPERTIES OF THE DRUG AMANTADINE AGAINST VIRUSES AND IN PARKINSON'S DISEASE

Zenodo (CERN European Organization for Nuclear Research)
Parkinson's Disease Mechanisms and Treatments
article

SPECIFIC PROPERTIES OF THE DRUG AMANTADINE AGAINST VIRUSES AND IN PARKINSON'S DISEASE

article en

Abstract

Long-term therapy of Parkinson's disease (PD) with dopaminergic agents is naturally accompanied by the appearance of symptom fluctuations and dyskinesias, and these complications are an extremely important factor that adversely affects the quality of life.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Openalex Percentile: Top 43%
Parkinson's Disease Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

SPECIFIC PROPERTIES OF THE DRUG AMANTADINE AGAINST VIRUSES AND IN PARKINSON'S DISEASE · Zenodo (CERN European Organization for Nuclear Research) (2025) | TGRS Research Map | TGRS